BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Y, Lin X, Lu X, Luo G, Zeng T, Tang J, Jiang F, Li L, Cui X, Huang W, Hou G, Chen X, Ouyang Q, Tang S, Sun H, Chen L, Gonzalez FJ, Wu M, Cong W, Chen L, Wang H. Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. Gut. 2016;65:1186-1201. [PMID: 26860770 DOI: 10.1136/gutjnl-2015-310318] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Ma X, Chen L, Yang Y, Zhang W, Wang P, Zhang K, Zheng B, Zhu L, Sun Z, Zhang S, Guo Y, Liang M, Wang H, Tian J. An Artificial Intelligent Signal Amplification System for in vivo Detection of miRNA. Front Bioeng Biotechnol 2019;7:330. [PMID: 31824932 DOI: 10.3389/fbioe.2019.00330] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Li D, Zeng Z. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis. Biosci Rep 2019;39:BSR20191815. [PMID: 31320544 DOI: 10.1042/BSR20191815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
3 Hu Y, Xie H, Liu Y, Liu W, Liu M, Tang H. miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells. Cancer Cell Int 2017;17:36. [PMID: 28286418 DOI: 10.1186/s12935-017-0407-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
4 Zhang Q, Li X, Li X, Li X, Chen Z. LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR-484 in human lung cancer cells. J Cell Biochem 2018;119:4447-57. [PMID: 29219208 DOI: 10.1002/jcb.26537] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
5 Qiu L, Huang Y, Li Z, Dong X, Chen G, Xu H, Zeng Y, Cai Z, Liu X, Liu J. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol 2019;13:441-55. [PMID: 30537115 DOI: 10.1002/1878-0261.12424] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
6 Mohamed DAW, Selim HM, Elmazny A, Genena A, Nabil MM. Apoptotic protease activating factor-1 gene and MicroRNA-484: A possible interplay in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 2022;58:103502. [PMID: 35030371 DOI: 10.1016/j.msard.2022.103502] [Reference Citation Analysis]
7 Xu M, Li XY, Song L, Tao C, Fang J, Tao L. miR-484 targeting of Yap1-induced LPS-inhibited proliferation, and promoted apoptosis and inflammation in cardiomyocyte. Biosci Biotechnol Biochem 2021;85:378-85. [PMID: 33604630 DOI: 10.1093/bbb/zbaa009] [Reference Citation Analysis]
8 El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res 2020;22:57-66. [PMID: 31956442 DOI: 10.1016/j.jare.2019.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
9 Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Letters 2018;412:283-8. [DOI: 10.1016/j.canlet.2017.10.008] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 26.8] [Reference Citation Analysis]
10 Chen S, Pu J, Bai J, Yin Y, Wu K, Wang J, Shuai X, Gao J, Tao K, Wang G, Li H. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res 2018;37:3. [PMID: 29316949 DOI: 10.1186/s13046-017-0670-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
11 Lu Y, Qin B, Hu H, Zhang J, Wang Y, Wang Q, Wang S. Integrative microRNA-gene expression network analysis in genetic hypercalciuric stone-forming rat kidney. PeerJ 2016;4:e1884. [PMID: 27069814 DOI: 10.7717/peerj.1884] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
12 Fang Z, Chen L. Personalized prediction of human diseases with single-sample dynamic network biomarkers. Biomark Med 2020;14:615-20. [PMID: 32530294 DOI: 10.2217/bmm-2020-0066] [Reference Citation Analysis]
13 Yu X, Zhang J, Sun S, Zhou X, Zeng T, Chen L. Individual-specific edge-network analysis for disease prediction. Nucleic Acids Res 2017;45:e170. [PMID: 28981699 DOI: 10.1093/nar/gkx787] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
14 Aguilar-bravo B, Sancho-bru P. Laser capture microdissection: techniques and applications in liver diseases. Hepatol Int 2019;13:138-47. [DOI: 10.1007/s12072-018-9917-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yi R, Feng J, Yang S, Huang X, Liao Y, Hu Z, Luo M. miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling. J Mol Histol 2018;49:209-18. [PMID: 29480405 DOI: 10.1007/s10735-018-9760-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
16 Guo X, Jin W, Chang C, Ding Y, Wang Y, Li L, Chen Y, Zhang J, Xu C, Chen G, Guo J. Large-scale quantitative genomics analyzes the circRNA expression profile and identifies the key circRNA in regulating cell proliferation during the proliferation phase of rat LR. Artif Cells Nanomed Biotechnol 2019;47:2957-66. [PMID: 31315467 DOI: 10.1080/21691401.2019.1640710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Lechel A, Gougelet A. Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions? Gut 2016;65:1073-4. [PMID: 26944073 DOI: 10.1136/gutjnl-2016-311446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614-622. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 229] [Article Influence: 41.8] [Reference Citation Analysis]
19 Tessitore A, Mastroiaco V, Vetuschi A, Sferra R, Pompili S, Cicciarelli G, Barnabei R, Capece D, Zazzeroni F, Capalbo C, Alesse E. Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model. Oncotarget 2017;8:53482-94. [PMID: 28881825 DOI: 10.18632/oncotarget.18585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ, Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World J Gastroenterol 2019; 25(16): 1936-1949 [PMID: 31086462 DOI: 10.3748/wjg.v25.i16.1936] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Wang RH, He LY, Zhou SH. The role of gene sculptor microRNAs in human precancerous lesions. Onco Targets Ther 2018;11:5667-75. [PMID: 30254459 DOI: 10.2147/OTT.S171241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
22 Lu XY, Chen D, Gu XY, Ding J, Zhao YJ, Zhao Q, Yao M, Chen Z, He XH, Cong WM. Predicting Value of ALCAM as a Target Gene of microRNA-483-5p in Patients with Early Recurrence in Hepatocellular Carcinoma. Front Pharmacol 2017;8:973. [PMID: 29375378 DOI: 10.3389/fphar.2017.00973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wang S, Wang W, Han X, Wang Y, Ge Y, Tan Z. Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma. J Biochem 2019;166:271-9. [PMID: 31157375 DOI: 10.1093/jb/mvz034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Zhou C, Bi F, Yuan J, Yang F, Sun S. Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6. J Exp Clin Cancer Res 2018;37:290. [PMID: 30482241 DOI: 10.1186/s13046-018-0951-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
25 In der Stroth L, Tharehalli U, Günes C, Lechel A. Telomeres and Telomerase in the Development of Liver Cancer. Cancers (Basel) 2020;12:E2048. [PMID: 32722302 DOI: 10.3390/cancers12082048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
26 Cheng Y, Chen T, Chen J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J Cancer 2020;11:7302-11. [PMID: 33193894 DOI: 10.7150/jca.49554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Lee D, Tang W, Dorsey TH, Ambs S. miR-484 is associated with disease recurrence and promotes migration in prostate cancer. Biosci Rep 2020;40:BSR20191028. [PMID: 32338277 DOI: 10.1042/BSR20191028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
28 Zare A, Ahadi A, Larki P, Omrani MD, Zali MR, Alamdari NM, Ghaedi H. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol Biol Rep 2018;45:1587-95. [PMID: 30171475 DOI: 10.1007/s11033-018-4278-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]